2456Loyola University of Chicago, Stritch School of Medicine, Maywood, IL, USA.
Department of Cardiology, 25815Loyola University Medical Center, Maywood, IL, USA.
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211014964. doi: 10.1177/10760296211014964.
Pulmonary embolism (PE) patients have an increased prevalence and incidence of atrial fibrillation (AF). Because comorbid AF increases risk of morbidity and mortality, we sought to investigate the role of thrombo-inflammatory biomarkers in risk stratifying patients who experience an acute PE episode. Study participants were enrolled from a Pulmonary Embolism Response Team (PERT) registry between March 2016 and March 2019 at Loyola University Medical Center and Gottlieb Memorial Hospital. This cohort was divided into 3 groups: PE patients with a prior diagnosis of AF (n = 8), PE patients with a subsequent diagnosis of AF (n = 11), and PE patients who do not develop AF (n = 71). D-dimer, CRP, PAI-1, TAFIa, FXIIIa, A2A, MP, and TFPI were profiled using the ELISA method. All biomarkers were significantly different between controls and PE patients ( < 0.05). Furthermore, TFPI was significantly elevated in PE patients who subsequently developed AF compared to PE patients who did not develop AF (157.7 ± 19.0 ng/mL vs. 129.0 ± 9.3 ng/mL, = 0.0386). This study suggests that thrombo-inflammatory biomarkers may be helpful in indicating an acute PE episode. Also, elevated TFPI levels may be associated with an increased risk of developing AF after a PE.
肺栓塞（PE）患者心房颤动（AF）的患病率和发生率增加。由于合并 AF 会增加发病率和死亡率的风险，我们试图研究血栓炎症生物标志物在急性 PE 发作患者危险分层中的作用。研究参与者于 2016 年 3 月至 2019 年 3 月在洛约拉大学医学中心和 Gottlieb 纪念医院的肺栓塞反应小组（PERT）登记处招募。该队列分为 3 组：有 AF 既往诊断的 PE 患者（n = 8）、有 AF 随后诊断的 PE 患者（n = 11）和不发生 AF 的 PE 患者（n = 71）。使用 ELISA 法对 D-二聚体、CRP、PAI-1、TAF Ia、FXIIIa、A2A、MP 和 TFPI 进行了分析。所有生物标志物在对照组和 PE 患者之间均有显著差异（<0.05）。此外，与未发生 AF 的 PE 患者相比，随后发生 AF 的 PE 患者的 TFPI 水平显著升高（157.7 ± 19.0 ng/mL 比 129.0 ± 9.3 ng/mL， = 0.0386）。这项研究表明，血栓炎症生物标志物可能有助于指示急性 PE 发作。此外，TFPI 水平升高可能与 PE 后发生 AF 的风险增加有关。
